Management of Hyperactive Delirium or Psychosis in Parkinson's Disease

First-Line Agent Selection

The American Geriatrics Society recommends pimavanserin as a first-line therapy for hallucinations and delusions associated with Parkinson's disease psychosis, as it demonstrates significant improvement in symptoms without impairing motor function 1
The 2019 American Geriatrics Society Beers Criteria recognizes pimavanserin as an exception to the general recommendation to avoid all antipsychotics in older adults with Parkinson's disease, due to its favorable motor safety profile 1

Quetiapine is an alternative option for symptomatic management of delirium, with a lower risk of extrapyramidal side effects, according to ESMO guidelines 2
The 2019 AGS Beers Criteria recognizes quetiapine as an acceptable exception for Parkinson's disease psychosis, despite limited evidence 1
Clozapine is highly effective for refractory cases, but its use is reserved due to the risk of agranulocytosis, requiring weekly blood monitoring 1

Haloperidol is contraindicated due to its lack of demonstrable benefit in mild-to-moderate delirium and significant worsening of Parkinson's motor symptoms through dopamine receptor blockade 4
First-generation antipsychotics like haloperidol carry a high risk of extrapyramidal side effects, particularly problematic in Parkinson's disease 2
Olanzapine should be avoided due to its significant motor function deterioration in Parkinson's disease patients, despite some evidence for delirium 4
The 2019 AGS Beers Criteria does not include olanzapine among the acceptable exceptions for Parkinson's disease psychosis, listing only quetiapine, clozapine, and pimavanserin 1

The American Geriatrics Society recommends using the lowest effective dose of antipsychotics for the shortest duration possible, as all antipsychotics carry risks in elderly patients with Parkinson's disease 2
Pharmacological interventions should be limited to patients with distressing symptoms or safety concerns, and monitoring for sedation, extrapyramidal symptoms, QT prolongation, and cognitive function is necessary 2
Benzodiazepines should not be used as initial treatment for delirium in patients not already taking them, as they increase confusion and fall risk 3
Not all atypical antipsychotics are safe in Parkinson's disease; only quetiapine, clozapine, and pimavanserin have acceptable motor safety profiles 1